BioCentury
ARTICLE | Finance

Higher ground

Despite the NBI's all-time high, biotech buysiders still see room to run

March 25, 2013 7:00 AM UTC

Although the NASDAQ Biotechnology Index reached another all-time high last week - a feat almost unthinkable to anyone who was around during the genomics bubble in 2000 - at least two buysiders think the market for biotechs still has room to run. Instead of a sell-off or rotation out of the sector, the performance of the market cap-weighted NBI could prompt investors to look for buying opportunities among smaller biotechs.

Prior to this month, the NBI's previous high was 1,597 on March 6, 2000. Almost 13 years later to the day, the index closed at 1,598. It ended last week at 1,627.76 (see "High Times"). ...